Avextra Unveils Promising Study Results at Major Pain CongressNew Data Highlights Superior Efficacy and Tolerability of Avextra 10/10 in Treating Chemotherapy-Induced Neuropathic Pain
Avextra Supports First Fully EU-Funded Psilocybin Therapy Study, Now Approved by EMABENSHEIM, Germany, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Avextra is proud to announce the EU approval of the groundbreaking PsyPal study, the first EU-funded research into psilocybin-assisted therapy, scheduled to commence in 2025. Supported by a €6.5 million grant from Horizon Europe—the EU's flagship program for research and innovation—this pioneering randomized controlled trial will examine psilocybin’s potential to ease psychological distress in palliative care patients across four European countries: Denmark, Portugal, the Netherlands, and Czechia.
